Baytril FDA Approved for Control of E. coli in Swine

January 14, 2015 — 

The U.S. Food and Drug Administration recently approved changes in the label claims for Baytril 100 (enrofloxacin). The drug may now be used intramuscularly or subcutaneously for the control of colibacillosis in groups of swine where E. coli has been diagnosed. This is in addition to the previous indication for treatment and control of swine respiratory disease. [Source: FDA and Bayer]

Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb). Administered dose volume should not exceed 5 mL per injection site. For the control of colibacillosis, administration should be initiated within the first 60 days post-weaning when clinical signs are present in at least 2% of the animals in the group. If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (U.S.A.) law prohibits the extra-label use of this drug in food-producing animals. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options.